-

Shareholder Alert: Robbins LLP Announces Colony Capital, Inc. (CLNY) Sued for Misleading Shareholders

SAN DIEGO & LOS ANGELES--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Colony Capital, Inc. (NYSE: CLNY) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 9, 2019 and May 7, 2020. Colony is a leading global investment firm with assets under management of $55 billion.

If you suffered a loss as a result of Colony's misconduct, click here.

Colony Capital, Inc. (CLNY) Accused of Misleading Shareholders

According to the complaint, on September 30, 2019, Colony announced that Blackstone (NYSE: BX) would acquire Colony Industrial, the industrial real estate assets and affiliated operating platform for $5.9 billion. Colony claimed the sale would "achieve compelling returns for [its] investors and generate significant liquidity." Then, on November 7, 2019, Colony Credit Real Estate (NYSE: CLNC) announced that after an expert valuation, it would begin reporting operations of its Core portfolio and Legacy, Non-Strategic portfolio separately. Unbeknownst to shareholders, Colony's sale of its industrial real estate portfolio and the bifurcation of its real estate portfolio were likely to negatively impact Colony's financial and operating results. On November 8, 2019, Colony revealed a GAAP net loss that "included reductions of goodwill, real estate and provision for loan losses totaling $540.3 million." Colony noted that $387 million of that loss was due to the pending sale of the Company's industrial investment management business as well as the decrease in management fees from Colony Real Estate, Inc. related to impairments due to its portfolio bifurcation. Colony's stock price fell almost 9% to close at $5.00 per share. Finally, on May 8, 2020, Colony disclosed that its portfolio companies had defaulted on $3.2 billion of debt and that Colony had received notice of acceleration covering $780 million of the defaulted debt. On this news, Colony's stock price fell almost 4% to close at $2.02 per share.

Colony Capital, Inc. (CLNY) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against Colony settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:CLNY

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, incl...
Back to Newsroom